{ "entity_id": "B-003290", "folder": "Haemovigilance-Advisory-Committee", "name": "Haemovigilance Advisory Committee", "type": "Statutory Body", "jurisdiction": "Commonwealth", "portfolio": "Health, Disability and Ageing", "website": "https://www.blood.gov.au/haemovigilance-reporting", "data_status": "rich", "completeness": { "has_strategy_brief": true, "has_strategy_structured": true, "has_vision": false, "has_kpi_targets": false, "has_kpi_results": false, "has_strategy_overview": true, "has_legislation_text": true, "has_legislation_structured": false, "has_global_initiatives_text": false, "has_global_initiatives_structured": false, "n_global_initiatives": 0, "has_ideas": true, "has_artifacts": true, "n_ideas": 12, "n_legislation": 0, "n_artifacts": 8, "n_kpi_targets": 0, "n_kpi_results": 0, "n_outcomes": 1, "verified_own_data": true }, "strategy_profile": { "status": "published", "confidence": "high", "summary": "The purpose of this document is to detail the required data elements for the National Blood Authority’s (NBA) Australian Haemovigilance Minimum Data Set (AHMDS).", "official_site_url": "https://www.blood.gov.au/haemovigilance-reporting", "source_documents": [ { "type": "strategie", "title": "Australian Haemovigilance Minimum Data Set", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf", "period": "2025", "confidence": "medium" }, { "type": "annual_report", "title": "Annual Report", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf", "period": "2025", "confidence": "high" }, { "type": "corporate_plan", "title": "Corporate Plan", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "period": "2025", "confidence": "high" } ], "purpose": { "text": "The purpose of this document is to detail the required data elements for the National Blood Authority’s (NBA) Australian Haemovigilance Minimum Data Set (AHMDS).", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": 4, "source_deep_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=4" }, "vision": null, "strategic_priorities": [], "values": [], "outcomes": [ { "name": "Outcome: Quality and Safety of Blood Transfusions", "description": "The AHMDS enables consistent data collection and analysis of transfusion related adverse events occurring in Australian health service organisations to improve the quality of national haemovigilance reporting.", "activities": [ "Data collection and analysis", "Reporting and monitoring" ], "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": 4, "source_deep_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=4" } ], "performance_measures": [], "document_alignment_terms": { "must_support": [ "The purpose of this document is to detail the required data elements for the National Blood Authority’s (NBA) Australian Haemovigilance Minimum Data Set (AHMDS)." ], "watch_terms": [], "avoid_claiming_without_evidence": [] }, "review_note": "" }, "global_initiatives": null, "strategy": { "reporting_period": "2024-25", "corporate_plan_period": "2025-26", "vision": null, "vision_source_page": null, "purposes": "The purpose of this document is to detail the required data elements for the National Blood Authority’s (NBA) Australian Haemovigilance Minimum Data Set (AHMDS).", "purposes_source_page": 4, "how_we_deliver": null, "how_we_deliver_source_page": null, "government_priorities": [], "outcomes": [ { "name": "Outcome: Quality and Safety of Blood Transfusions", "description": "The AHMDS enables consistent data collection and analysis of transfusion related adverse events occurring in Australian health service organisations to improve the quality of national haemovigilance reporting.", "key_activities": [ "Data collection and analysis", "Reporting and monitoring" ], "source_page": 4 } ], "values": [], "values_framework_name": null, "kpi_targets_2025_26": [], "kpi_results_2024_25": [], "_source_urls": { "annual_report_url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf", "corporate_plan_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf" } }, "ideas": [ { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Data & Performance", "scale": "small", "title": "KPI evidence register with named owners", "idea": "Create a simple register mapping each KPI to source data, owner, frequency, target, and last result.", "quote": "[Page 18]\nPatient—outcome severity\nIdentifying and definitional attributes\nMetadata item type: Data Element\nShort name: Outcome severity\nMETEOR identifier: Not applicable\nDefinition: Hierarchical categories to define harm done to the patient\nas a result of an adverse event. ∧\nData Element Concept: Patient—outcome severity\nRepresentational attributes\nRepresentation class: Code\nData type: String\nFormat: [X(21)]\nMaximum character length: 21\nPermissible values:\nValue Meaning\nNo morbidity No ill effects, no clinical effects\nMinor The recipient may have required medical\nmorbidity intervention (such as symptomatic\ntreatment) but lack of such would not\nhave resulted in permanent damage or\nimpairment of a body function\nSevere The recipient required in-patient\nmorbidity hospitalisation or prolongation of\nhospitalisation directly attributable to the\nevent; and/or\n- the adverse event resulted in", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Executives / Parliament / public", "source": "strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Data & Performance", "scale": "large", "title": "Outcome dashboard linking budget, delivery, and public impact", "idea": "Build a public-facing outcome dashboard showing spend, outputs, outcomes, and delivery confidence.", "quote": "[Page 18]\nPatient—outcome severity\nIdentifying and definitional attributes\nMetadata item type: Data Element\nShort name: Outcome severity\nMETEOR identifier: Not applicable\nDefinition: Hierarchical categories to define harm done to the patient\nas a result of an adverse event. ∧\nData Element Concept: Patient—outcome severity\nRepresentational attributes\nRepresentation class: Code\nData type: String\nFormat: [X(21)]\nMaximum character length: 21\nPermissible values:\nValue Meaning\nNo morbidity No ill effects, no clinical effects\nMinor The recipient may have required medical\nmorbidity intervention (such as symptomatic\ntreatment) but lack of such would not\nhave resulted in permanent damage or\nimpairment of a body function\nSevere The recipient required in-patient\nmorbidity hospitalisation or prolongation of\nhospitalisation directly attributable to the\nevent; and/or\n- the adverse event resulted in", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Executives / Parliament / public", "source": "strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Risk & Assurance", "scale": "small", "title": "Recommendation tracker for audits, reviews, and inquiries", "idea": "Publish a single internal tracker for audit/review recommendations, owners, due dates, and implementation evidence.", "quote": "[Page 15]\nTable 9 highlights that 68% of adverse events were reported to be related to red cell transfusions,\ncompared to red cells units issued being 62% of total fresh blood products issued in 2020-21,\nfollowed by platelets (14%) and fresh frozen plasma (8%).", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Executives / assurance teams", "source": "other-pdfs/Haemovigilance-20Report-202020-21.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-03/Haemovigilance%20Report%202020-21.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Risk & Assurance", "scale": "large", "title": "Integrated assurance and lessons-learned system", "idea": "Create an assurance system that connects audit findings, risk registers, delivery reviews, and investment decisions.", "quote": "[Page 15]\nTable 9 highlights that 68% of adverse events were reported to be related to red cell transfusions,\ncompared to red cells units issued being 62% of total fresh blood products issued in 2020-21,\nfollowed by platelets (14%) and fresh frozen plasma (8%).", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Executives / assurance teams", "source": "other-pdfs/Haemovigilance-20Report-202020-21.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-03/Haemovigilance%20Report%202020-21.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Citizen Services", "scale": "small", "title": "Plain-language service pages and proactive status updates", "idea": "Rewrite high-volume pages and letters into plain language, add status notifications, and measure contact reduction.", "quote": "[Page 13]\n118 Retail sale/supplier of medical goods – hearing\naids\n119 Retail sale/supplier of medical goods –\ndispensing community pharmacist\n120 Retail sale/supplier of medical goods – other\n121 Public health program service provider\n122 General health administration service\nprovider\n123 Private health insurance\n188 Other Main Health Care Service providers\n198 Regional health service not further defined\n199 State/territory health authority not further\ndefined\n200 Secondary/non-Health Care Services\norganisation\n201 Pharmaceutical industry\n202 University\n203 Non-health related insurance\n204 Residential aged care facility\n288 Other Secondary/non-Health Care Services\norganisation\nCollection and usage attributes\nGuide for use: It is anticipated that only codes 101, 102, or 103 will be\nreported to the National Haemovigilance Program.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Citizens / service users", "source": "strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Citizen Services", "scale": "large", "title": "Single front door for life-event based services", "idea": "Bundle services around life events so citizens can complete related steps across agencies in one journey.", "quote": "[Page 13]\n118 Retail sale/supplier of medical goods – hearing\naids\n119 Retail sale/supplier of medical goods –\ndispensing community pharmacist\n120 Retail sale/supplier of medical goods – other\n121 Public health program service provider\n122 General health administration service\nprovider\n123 Private health insurance\n188 Other Main Health Care Service providers\n198 Regional health service not further defined\n199 State/territory health authority not further\ndefined\n200 Secondary/non-Health Care Services\norganisation\n201 Pharmaceutical industry\n202 University\n203 Non-health related insurance\n204 Residential aged care facility\n288 Other Secondary/non-Health Care Services\norganisation\nCollection and usage attributes\nGuide for use: It is anticipated that only codes 101, 102, or 103 will be\nreported to the National Haemovigilance Program.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Citizens / service users", "source": "strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Staff Productivity", "scale": "small", "title": "Reusable briefing and summary assistant for internal documents", "idea": "Create controlled templates for summarising reports, submissions, minutes, and ministerial briefs.", "quote": "[pages 25,26,27]\nance in\nresponse to targeted messaging for pre-donation fluid intake and in-centre applied muscle tensing\nexercises, staff phlebotomy excellence training, the change to a smaller gauge needle and\nexperience with the plasma machines introduced from May 2019.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "APS staff / executives", "source": "other-pdfs/Haemovigilance-20Report-202021-22.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-03/Haemovigilance%20Report%202021-22.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Sensitive information leakage", "Inconsistent quality of generated drafts" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Staff Productivity", "scale": "large", "title": "Department-wide knowledge and briefing platform", "idea": "Build a secure knowledge platform that lets staff search, summarise, and cite approved departmental material.", "quote": "[pages 25,26,27]\nance in\nresponse to targeted messaging for pre-donation fluid intake and in-centre applied muscle tensing\nexercises, staff phlebotomy excellence training, the change to a smaller gauge needle and\nexperience with the plasma machines introduced from May 2019.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "APS staff / executives", "source": "other-pdfs/Haemovigilance-20Report-202021-22.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-03/Haemovigilance%20Report%202021-22.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Sensitive information leakage", "Inconsistent quality of generated drafts" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Case Processing", "scale": "small", "title": "Triage queue for stuck or ageing cases", "idea": "Use existing case data to flag ageing, duplicate, incomplete, or high-risk cases for earlier intervention.", "quote": "Product defect A product defect is blood or a blood String 5 True or\ncomponent which does not meet the quality, False\nsafety and efficacy requirements set in the\nTherapeutic Goods Order No.1021 and 882\napproved under the Therapeutic Goods Act\n1989 or which contains (remaining)\ncontaminating agents despite screening,\ntesting and processing having been undertaken\nproperly (e.g. product discarded after positive\ninfection test result following a window\nperiod).", "impact": "Medium", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Applicants / case officers", "source": "strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Case Processing", "scale": "large", "title": "End-to-end case processing redesign", "idea": "Redesign the case pathway around risk-based triage, reusable evidence, and automated eligibility checks.", "quote": "Product defect A product defect is blood or a blood String 5 True or\ncomponent which does not meet the quality, False\nsafety and efficacy requirements set in the\nTherapeutic Goods Order No.1021 and 882\napproved under the Therapeutic Goods Act\n1989 or which contains (remaining)\ncontaminating agents despite screening,\ntesting and processing having been undertaken\nproperly (e.g. product discarded after positive\ninfection test result following a window\nperiod).", "impact": "High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Applicants / case officers", "source": "strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Citizen Participation", "scale": "small", "title": "Consultation feedback summaries with response tracking", "idea": "Summarise consultation submissions by theme and publish what changed in response.", "quote": "[Page 13]\n118 Retail sale/supplier of medical goods – hearing\naids\n119 Retail sale/supplier of medical goods –\ndispensing community pharmacist\n120 Retail sale/supplier of medical goods – other\n121 Public health program service provider\n122 General health administration service\nprovider\n123 Private health insurance\n188 Other Main Health Care Service providers\n198 Regional health service not further defined\n199 State/territory health authority not further\ndefined\n200 Secondary/non-Health Care Services\norganisation\n201 Pharmaceutical industry\n202 University\n203 Non-health related insurance\n204 Residential aged care facility\n288 Other Secondary/non-Health Care Services\norganisation\nCollection and usage attributes\nGuide for use: It is anticipated that only codes 101, 102, or 103 will be\nreported to the National Haemovigilance Program.", "impact": "Medium", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Citizens / stakeholders / policy teams", "source": "strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Citizen Participation", "scale": "large", "title": "Always-on policy participation platform", "idea": "Create a standing participation platform where citizens and stakeholders can propose, vote, and track ideas.", "quote": "[Page 13]\n118 Retail sale/supplier of medical goods – hearing\naids\n119 Retail sale/supplier of medical goods –\ndispensing community pharmacist\n120 Retail sale/supplier of medical goods – other\n121 Public health program service provider\n122 General health administration service\nprovider\n123 Private health insurance\n188 Other Main Health Care Service providers\n198 Regional health service not further defined\n199 State/territory health authority not further\ndefined\n200 Secondary/non-Health Care Services\norganisation\n201 Pharmaceutical industry\n202 University\n203 Non-health related insurance\n204 Residential aged care facility\n288 Other Secondary/non-Health Care Services\norganisation\nCollection and usage attributes\nGuide for use: It is anticipated that only codes 101, 102, or 103 will be\nreported to the National Haemovigilance Program.", "impact": "High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Citizens / stakeholders / policy teams", "source": "strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] } ], "legislation_administered": [], "artifacts": [ { "category": "strategies", "year": "2025", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf", "file": "strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf", "bytes": 1753476, "link_text": "Australian Haemovigilance Minimum Data Set" }, { "category": "other-pdfs", "year": "2022-23", "url": "https://www.blood.gov.au/sites/default/files/documents/2026-02/Haemovigilance%20Report%202022-23.pdf", "file": "other-pdfs/Haemovigilance-20Report-202022-23.pdf", "bytes": 2391986, "link_text": "Haemovigilance Report 2022-23 (pdf)" }, { "category": "other-pdfs", "year": "2021-22", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-03/Haemovigilance%20Report%202021-22.pdf", "file": "other-pdfs/Haemovigilance-20Report-202021-22.pdf", "bytes": 1421478, "link_text": "Haemovigilance Report 2021-22 (pdf)" }, { "category": "other-pdfs", "year": "2020-21", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-03/Haemovigilance%20Report%202020-21.pdf", "file": "other-pdfs/Haemovigilance-20Report-202020-21.pdf", "bytes": 1585373, "link_text": "Haemovigilance Report 2020-21 (pdf)" }, { "category": "other-pdfs", "year": "2019-20", "url": "https://www.blood.gov.au/sites/default/files/documents/2024-06/Australian%20haemovigilance%20data%20at%20a%20glance%202019-20.pdf", "file": "other-pdfs/Australian-20haemovigilance-20data-20at-20a-20glance-202019-20.pdf", "bytes": 349393, "link_text": "Australian Haemovigilance at a Glance 2019-20 (pdf)" }, { "category": "other-pdfs", "year": "2019-20", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf", "file": "other-pdfs/Haemovigilance-20Report-202019-20.pdf", "bytes": 1399136, "link_text": "Australian Haemovigilance Report 2019-20 (pdf)" }, { "category": "annual-reports", "year": "2025", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf", "file": "annual-reports/2025.pdf", "bytes": 3522745, "link_text": "Annual Report" }, { "category": "corporate-plans", "year": "2025", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "file": "corporate-plans/2025.pdf", "bytes": 6435684, "link_text": "Corporate Plan" } ], "_meta": { "snapshot_built_at": "2026-05-14T02:12:58+00:00", "strategy_brief_meta": { "model": "nova-micro", "folder": "Haemovigilance-Advisory-Committee", "annual_report": { "file": null, "url": "", "year": null }, "corporate_plan": { "file": "strategies\\AHMDS-20--20Oct-202024-20--20FINAL-20pdf.txt", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf", "year": "AHMDS-20--20Oct-202024-20--20FINAL-20pdf" }, "usage": { "input_tokens": 11917, "output_tokens": 276, "total_tokens": 12193, "model": "nova-micro" }, "cost_usd": 0.000455735, "elapsed_seconds": 2.24, "generated_at": "2026-05-13T10:33:31+00:00" }, "ideas_manifest": { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "generated_at": "2026-05-09T23:05:41.455399+00:00", "idea_count": 12, "markdown": "ideas/Haemovigilance-Advisory-Committee_ideas.md", "jsonl": "ideas/ideas.jsonl", "inputs": [ "Haemovigilance-Advisory-Committee_strategy-overview.md", "strategy-evidence.json", "global-intelligence/source-manifest.json" ] }, "global_intel_meta": null } }